Table 1.

Characteristics of prostate cancer cases (1982–2005) overall and according to quintile of cumulative average vigorous physical activity in the HPFS.

Cases according to vigorous activity quintile
CharacteristicsAll cases12345
Number1182423242324
Age at diagnosis, years (mean, SD)65.1 (6.7)66.6 (6.1)64.7 (6.8)65.2 (6.7)64.9 (7.0)63.9 (7.2)
Year of diagnosis, N (%)
 Before 19909 (8)4 (17)1 (4)1 (4)1 (4)2 (8)
 1990–199320 (17)4 (17)3 (13)5 (21)8 (35)0 (0)
 After 199389 (75)16 (67)19 (83)18 (75)14 (61)22 (92)
PSA Level, ng/mL, median (Q1, Q3)a7.0 (5.3, 12.7)8.8 (5.8, 18.9)8.3 (6.3, 10.5)7.2 (4.8, 11.1)6.0 (5.3, 14.7)5.2 (4.0, 7.0)
Pathologic Gleason score, N (%)
 68 (7)0 (0)0 (0)4 (17)3 (13)1 (4)
 781 (69)20 (83)15 (65)14 (58)13 (57)19 (79)
 8–1029 (25)4 (17)8 (35)6 (25)7 (30)4 (17)
Clinical stage, N (%)b
 T1/T292 (81)17 (71)19 (83)21 (88)13 (57)22 (92)
 T312 (11)3 (13)2 (9)2 (8)4 (17)1 (4)
 T4/N1/M19 (8)1 (4)1 (4)1 (4)5 (22)1 (4)
Lethal, N (%)44 (37)12 (50)8 (35)7 (29)11 (48)6 (25)
Total activity, MET-h/wk, median (Q1, Q3)c26.3 (15.2, 41.2)14.0 (7.5, 25.2)19.4 (7.4, 26.0)26.9 (16.4, 36.3)28.0 (19.3, 41.2)44.6 (35.7, 57.8)
Vigorous activity, MET-h/wk, median (Q1, Q3)c4.4 (0.7, 12.8)0.1 (0.0, 0.1)1.3 (0.7, 2.4)4.4 (4.1, 5.0)11.3 (9.0, 12.7)28.9 (25.3, 34.5)
  • Note: Percentages may not sum to 100 due to rounding.

  • Abbreviation: PSA, prostate-specific antigen

  • aPSA at diagnosis was missing for 21 men.

  • bClinical TNM stage was missing for 5 men.

  • cValues are cumulative averages updated from baseline to prostate cancer diagnosis.